Opinion|Videos|December 17, 2025

Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL

Name: Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL
Uploaded: 2025-12-17T13:00:00.000Z
Duration: 1 min 30 s
Description: Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL

Author(s)Marc S. Hoffmann, MD

Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia at the 2025 ASH Meeting.

Episodes in this series

Now Playing

EP. 1 Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL

Marc S. Hoffmann, MD, discusses 6-year data from the phase 3 SEQUOIA study, which evaluated the BTK inhibitor zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia. The results were presented at the 2025 ASH Annual Meeting. Hoffman shares long-term progression free survival outcomes for 2 of the study arms: Arm A, in which patients without del(17p) received zanubrutinib monotherapy and were compared to a group of patients who received bendamustine and rituximab; and the nonrandomized Arm C, in whichpatients with del(17p) received zanubrutinib monotherapy.

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL

Episodes in this series

EP. 1 Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL

Newsletter

Related Content

ctDNA Utilization in Early-Stage NSCLC

Utilizing NCCN Guideline Recommendations in Biomarker Testing

Exploring Investigational Therapies in Low-risk MDS

Imetelstat as a Second-line Therapy Option in Low-risk MDS

The Effects of Luspatercept on Hemoglobin Levels

Latest CME

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

43rd Annual Miami Breast Cancer Conference®

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

25th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® West

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

24th Annual International Congress on the Future of Breast Cancer® East

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

24th Annual School of Breast Oncology

9th Annual School of Nursing Oncology™

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

School of Breast Oncology® (SOBO) Slide & Lecture Library

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer

Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma

FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer

Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes

Early Relapse Guides Use of CAR T vs Other Options in LBCL